The Cardiovascular Toxicity of Selective and Nonselective Cyclooxygenase Inhibitors: Comparisons, Contrasts, and Aspirin Confounding

The premature suspension of the Alzheimer Disease Anti‐inflammatory Prevention (ADAPT) and the Adenoma Prevention with Celecoxib (APC) trials prompted intense review of the cardiovascular safety profile of selective and nonselective cyclooxygenase (COX) inhibitors. This article reviews the current state of selective COX‐2 inhibitors, discusses the mechanistic evidence underlying the cardiovascular risk associated with selective COX‐2 inhibition, outlines the pharmacodynamics of aspirin effects on platelets and the interference of propionic acid derivatives (ibuprofen and naproxen) with these effects, and poses that aspirin confounding may have led to the erroneous conclusion of naproxen‐associated adverse cardiovascular outcomes in the ADAPT trial. Finally, recommendations regarding selective COX‐2 inhibitors and appropriate timing of aspirin coadministration with traditional NSAIDs are proposed in relevance to patient safety and future trial design.

[1]  D. Lehmann.  Arthritis medications and cardiovascular events. , 2005, JAMA.

[2]  Marc A Pfeffer,et al.  Cardiovascular Risk Associated With Celecoxib in a Clinical Trial for Colorectal Adenoma Prevention , 2005, The New England journal of medicine.

[3]  Robert Riddell,et al.  Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. , 2005, The New England journal of medicine.

[4]  B. Psaty,et al.  COX-2 inhibitors--lessons in drug safety. , 2005, The New England journal of medicine.

[5]  Andreas Hoeft,et al.  Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. , 2005, The New England journal of medicine.

[6]  E. Topol.  Arthritis medicines and cardiovascular events--"house of coxibs". , 2005, JAMA.

[7]  M. Egger,et al.  Risk of cardiovascular events and rofecoxib: cumulative meta-analysis , 2004, The Lancet.

[8]  G. FitzGerald.  Coxibs and cardiovascular disease. , 2004, The New England journal of medicine.

[9]  T. Schnitzer,et al.  Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial , 2004, The Lancet.

[10]  T. Schnitzer,et al.  Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial , 2004, The Lancet.

[11]  Sebastian Schneeweiss,et al.  Relationship Between Selective Cyclooxygenase-2 Inhibitors and Acute Myocardial Infarction in Older Adults , 2004, Circulation.

[12]  Garret A. FitzGerald,et al.  COX-2 and beyond: approaches to prostaglandin inhibition in human disease , 2003, Nature Reviews Drug Discovery.

[13]  K. Davis,et al.  Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. , 2003, JAMA.

[14]  P. Duke,et al.  Efficacy and safety of the cyclooxygenase 2 inhibitors parecoxib and valdecoxib in patients undergoing coronary artery bypass surgery. , 2003, The Journal of thoracic and cardiovascular surgery.

[15]  M. Chavez,et al.  Valdecoxib: a review. , 2003, Clinical therapeutics.

[16]  J. Morrow,et al.  Opposite effects of cyclooxygenase-1 and -2 activity on the pressor response to angiotensin II. , 2002, The Journal of clinical investigation.

[17]  J. Eikelboom,et al.  Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. , 2002, The New England journal of medicine.

[18]  C. Meinert,et al.  Double placebo design in a prevention trial for Alzheimer's disease. , 2002, Controlled clinical trials.

[19]  H. S. Kim,et al.  Deficiency of COX-1 causes natriuresis and enhanced sensitivity to ACE inhibition. , 2001, Kidney international.

[20]  R Day,et al.  Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. , 2000, The New England journal of medicine.

[21]  B. Gertz,et al.  Comparative Inhibitory Activity of Rofecoxib, Meloxicam, Diclofenac, Ibuprofen, and Naproxen on COX‐2 versus COX‐1 in Healthy Volunteers , 2000, Journal of clinical pharmacology.

[22]  M. Malkowski,et al.  The productive conformation of arachidonic acid bound to prostaglandin synthase. , 2000, Science.

[23]  R. Makuch,et al.  Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. , 2000, JAMA.

[24]  G. Garcı́a-Cardeña,et al.  Endothelial Dysfunction, Hemodynamic Forces, and Atherogenesis a , 2000, Annals of the New York Academy of Sciences.

[25]  R. Garavito,et al.  Cyclooxygenases: structural, cellular, and molecular biology. , 2000, Annual review of biochemistry.

[26]  Lise,et al.  Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. , 2000, The New England journal of medicine.

[27]  J. Mitchell,et al.  Cyclo‐oxygenase‐2: pharmacology, physiology, biochemistry and relevance to NSAID therapy , 1999, British journal of pharmacology.

[28]  G. FitzGerald,et al.  Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids. , 1999, The Journal of pharmacology and experimental therapeutics.

[29]  G. FitzGerald,et al.  Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[30]  P. Lipsky,et al.  Cyclooxygenase in biology and disease , 1998, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[31]  J. Vane,et al.  Cyclooxygenases 1 and 2. , 1998, Annual review of pharmacology and toxicology.

[32]  S. Narumiya,et al.  Altered pain perception and inflammatory response in mice lacking prostacyclin receptor , 1997, Nature.

[33]  K. Seibert,et al.  Distribution of COX-1 and COX-2 in normal and inflamed tissues. , 1997, Advances in experimental medicine and biology.

[34]  P. Loll,et al.  Synthesis and use of iodinated nonsteroidal antiinflammatory drug analogs as crystallographic probes of the prostaglandin H2 synthase cyclooxygenase active site. , 1996, Biochemistry.

[35]  Daniel Picot,et al.  The structural basis of aspirin activity inferred from the crystal structure of inactivated prostaglandin H2 synthase , 1995, Nature Structural Biology.

[36]  Walker,et al.  Collaborative overview of randomised trials of antiplatelet therapy Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients , 1994 .

[37]  Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration. , 1994, BMJ.

[38]  G. FitzGerald.  Mechanisms of platelet activation: thromboxane A2 as an amplifying signal for other agonists. , 1991, The American journal of cardiology.

[39]  G. FitzGerald,et al.  Human platelet/erythroleukemia cell prostaglandin G/H synthase: cDNA cloning, expression, and gene chromosomal assignment , 1991, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[40]  W. Smith,et al.  Immunochemical and kinetic evidence for two different prostaglandin H-prostaglandin E isomerases in sheep vesicular gland microsomes. , 1987, The Journal of biological chemistry.

[41]  G. FitzGerald,et al.  Inhibition of thromboxane formation in vivo and ex vivo: implications for therapy with platelet inhibitory drugs. , 1987, Blood.

[42]  L Roy,et al.  Platelet activation in unstable coronary disease. , 1986, The New England journal of medicine.

[43]  G. Davı̀,et al.  Clinical pharmacology of platelet cyclooxygenase inhibition. , 1985, Circulation.

[44]  A. K. Pedersen,et al.  Increased prostacyclin biosynthesis in patients with severe atherosclerosis and platelet activation. , 1984, The New England journal of medicine.

[45]  C. Patrono,et al.  Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects. , 1982, The Journal of clinical investigation.

[46]  J. Vane,et al.  Prostacyclin and the vascular endothelium. , 1981, Bulletin europeen de physiopathologie respiratoire.